The FY2024 (Dec) proxy of Eli Lilly & Co names 15 peer companies for pay. Among Eli Lilly & Co and these peers, CEO pay was the highest of 7 and total shareholder return was the highest of 7.
1st highest of 7in Eli Lilly & Co and its pay peers, FY2024 (Dec) by CEO pay:
1st highest of 7in Eli Lilly & Co and its pay peers, FY2024 (Dec) by total shareholder return:
Pay peer group, FY2024 (Dec) proxy
| Pfizer | ||
| Amgen | ||
| Johnson & Johnson | ||
| Biogen | ||
| Bristol Myers Squibb | ||
| AbbVie | ||
| AstraZeneca | Not disclosed | Not disclosed |
| Gilead | Not disclosed | Not disclosed |
| GlaxoSmithKline | Not disclosed | Not disclosed |
| Merck | Not disclosed | Not disclosed |
| Novartis | Not disclosed | Not disclosed |
| Novo Nordisk | Not disclosed | Not disclosed |
| Roche | Not disclosed | Not disclosed |
| Sanofi | Not disclosed | Not disclosed |
| Takeda | Not disclosed | Not disclosed |
PSU comparator group
The companies that relative total shareholder return is measured against for performance stock units.
| Johnson & Johnson | ||
| AbbVie | ||
| Pfizer | ||
| Amgen | ||
| Bristol Myers Squibb | ||
| Stryker | ||
| AstraZeneca | Not disclosed | Not disclosed |
| Biogen | Not disclosed | Not disclosed |
| Gilead | Not disclosed | Not disclosed |
| GlaxoSmithKline | Not disclosed | Not disclosed |
| Medtronic | Not disclosed | Not disclosed |
| Merck | Not disclosed | Not disclosed |
| Novartis | Not disclosed | Not disclosed |
| Novo Nordisk | Not disclosed | Not disclosed |
| Roche | Not disclosed | Not disclosed |
| Sanofi | Not disclosed | Not disclosed |
| Takeda | Not disclosed | Not disclosed |
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.